[24] Desai SD, Li TK,

Rodriguez-Bauman A, Liu LF, Rubin EH. Ubiquitin/26s proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Research. 2001;**61**(15):5926-5932

[25] Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: Update and perspectives. Cancer Chemotherapy and Pharmacology. 1993;**32**(2):103-108

[26] Jansen WJM, Zwart B, Hulscher STM, Giaccone G, Pinedo HM, Boven E. CPT-11 in human coloncancer cell lines and xenografts: Characterization of cellular sensitivity determinants. International Journal of Cancer. 1997;**70**(3):335-340

[27] Sorensen M, Sehested M, Jensen P. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. British Journal of Cancer. 1995;**72**(2):399-404

[28] Madelaine I, Prost S, Naudin A, Riou G, Lavelle F, Riou J-F. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochemical Pharmacology. 1993;**45**(2):339-348

[29] Gongora C, Vezzio-Vie N, Tuduri S, Denis V, Causse A, Auzanneau C, et al. New Topoisomerase I mutations are associated with resistance to camptothecin. Molecular Cancer. 2011;**10**(1):64

[30] Tesauro C, Morozzo Della Rocca B, Ottaviani A, Coletta A, Zuccaro L, Arnò B, et al. Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico. Molecular Cancer. 2013;**12**(1):100

[31] Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco GS. Topoisomerase I inhibitors: Selectivity and cellular resistance. Drug Resistance Updates. 1999;**2**(5):307-318

*Simple and Fast DNA-Based Tool to Investigate Topoisomerase 1 Activity, a Biomarker for Drug… DOI: http://dx.doi.org/10.5772/intechopen.105758*

[32] Kjeldsen E, Bonven BJ, Andoh T, Ishii K, Okada K, Bolund L, et al. Characterization of a camptothecinresistant human DNA topoisomerase I. The Journal of Biological Chemistry. 1988;**263**(8):3912-3916

[33] Gaillard H, García-Muse T, Aguilera A. Replication stress and cancer. Nature Reviews. Cancer. 2015;**15**:276-280

[34] Macheret M, Halazonetis TD. DNA replication stress as a hallmark of cancer. Annual Review of Pathology: Mechanisms of Disease. 2015;**10**:425-448

[35] Kotsantis P, Silva LM, Irmscher S, Jones RM, Folkes L, Gromak N, et al. Increased global transcription activity as a mechanism of replication stress in cancer. Nature Communications. 2016;**7**:13087

[36] Kowalska-Loth B, Girstun A, Derlacz R, Staroń K. Activation of human topoisomerase I by protein kinase CK2. Molecular Biology Reports. 2003 Jun;**30**(2):107-111

[37] Seet BT, Dikic I, Zhou MM, Pawson T. Reading protein modifications with interaction domains. Nature Reviews. Molecular Cell Biology. 2006;**7**(7):473-83

[38] Nitiss JL, Kiianitsa K, Sun Y, Nitiss KC, Maizels N. Topoisomerase assays. Current Protocols. 2021;**1**:10

[39] Frøhlich RF, Andersen FF, Westergaard O, Andersen AH, Knudsen BR. Regions within the N-terminal domain of human topoisomerase I exert important functions during strand rotation and DNA binding. Journal of Molecular Biology. 2004;**336**(1):93-103

[40] Martín-Encinas E, Selas A, Tesauro C, Rubiales G, Knudsen BR, Palacios F, et al. Synthesis of novel hybrid quinolino[4,3-b][1,5] naphthyridines and quinolino[4,3-b] [1,5]naphthyridin-6(5H)-one derivatives and biological evaluation as topoisomerase I inhibitors and antiproliferatives. European Journal of Medicinal Chemistry. 2020;**195**:112292

[41] Jensen NF, Agama K, Roy A, Smith DH, Pfister TD, Rømer MU, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. Journal of Experimental & Clinical Cancer Research. 2016;**35**(1):56

[42] Tesauro C, Keller JG, Gromova I, Gromov P, Frohlich R, Erlandsen JU, et al. Different camptothecin sensitivities in subpopulations of colon cancer cells correlate with expression of different phospho-isoforms of Topoisomerase I with different activities. Cancers (Basel). 2020;**12**(5):1240

[43] Nitiss JL, Soans E, Rogojina A, Seth A, Mishina M. Topoisomerase assays. Current Protocol Pharmacology. 2012. Chapter 3

[44] Christiansen K, Westergaard O. Characterization of intra- and intermolecular DNA ligation mediated by eukaryotic topoisomerase I. Role of bipartite DNA interaction in the ligation process. The Journal of Biological Chemistry. 1994;**269**(1):721-729

[45] Svejstrup JQ, Christiansen K, Andersen AH, Lund K, Westergaard O. Minimal DNA duplex requirements for topoisomerase I-mediated cleavage in vitro. The Journal of Biological Chemistry. 1990;**265**(21):12529-12535

[46] Tesauro C, Fiorani P, D'Annessa I, Chillemi G, Turchi G, Desideri A. Erybraedin C, a natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human

topoisomerase I. The Biochemical Journal. 2010;**425**(3):531-539

[47] Anand J, Sun Y, Zhao Y, Nitiss KC, Nitiss JL. Detection of topoisomerase covalent complexes in eukaryotic cells. Methods in Molecular Biology. 2018;**1703**:283-299

[48] Stougaard M, Lohmann JS, Mancino A, Celik S, Andersen FF, Koch J, et al. Single-molecule detection of human topoisomerase I cleavageligation activity. ACS Nano. 2009;**3**(1):223-233

[49] Proszek J, Roy A, Jakobsen AK, Frøhlich R, Knudsen BR, Stougaard M. Topoisomerase I as a biomarker: Detection of activity at the single molecule level. Sensors (Switzerland). 2014;**14**(1):1195-1207

[50] Keller JG, Tesauro C, Coletta A, Graversen AD, Ho Y-P, Kristensen P, et al. On-slide detection of enzymatic activities in selected single cells. Nanoscale. 2017;**9**(36):13546-13553

[51] Keller JG, Stougaard M, Knudsen BR. Enzymatic activity in single cells. Methods in Enzymology. 2019;**628**:43-57

[52] Jakobsen AK, Lauridsen KL, Samuel EB, Proszek J, Knudsen BR, Hager H, et al. Correlation between topoisomerase I and tyrosyl-DNA phosphodiesterase 1 activities in non-small cell lung cancer tissue. Experimental and Molecular Pathology. 2015;**99**(1):56-64

[53] Petersen KV, Selas A, Hymøller KM, Mizielinski K, Thorsager M, Stougaard M, et al. Simple and fast dna based sensor system for screening of small-molecule compounds targeting eukaryotic topoisomerase 1. Pharmaceutics. 2021;**1**:13(8)

[54] Rasband WS. ImageJ [Software]. Bethesda, Maryland, USA: U S National Institute of Health; 2015

[55] Colorectal Cancer Chemotherapy. Chemo for Colon & Rectal Cancer. Available from: https://www.cancer.org/ cancer/colon-rectal-cancer/treating/ chemotherapy.html

[56] Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase i inhibition in colorectal cancer: Biomarkers and therapeutic targets. British Journal of Cancer. 2012;**106**(1):18-24

[57] Palshof JA, Høgdall EVS, Poulsen TS, Linnemann D, Jensen BV, Pfeiffer P, et al. Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. BMC Cancer. 2017;**17**(1):48

[58] Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS Trial. Journal of Clinical Oncology. 2008;**26**(16)

[59] Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, et al. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): A model for randomised controlled trials in the era of personalised medicine? British Journal of Cancer. 2014;**110**(9):2178-2186

[60] Koopman M, Knijn N, Richman S, Seymour M, Quirke P, Van TH, et al. The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG). European Journal of Cancer Supplements. 2009;**7**(2):321-322
